IN2012DN02696A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02696A
IN2012DN02696A IN2696DEN2012A IN2012DN02696A IN 2012DN02696 A IN2012DN02696 A IN 2012DN02696A IN 2696DEN2012 A IN2696DEN2012 A IN 2696DEN2012A IN 2012DN02696 A IN2012DN02696 A IN 2012DN02696A
Authority
IN
India
Application number
Inventor
Jean-Francois Haeuw
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of IN2012DN02696A publication Critical patent/IN2012DN02696A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2696DEN2012 2009-10-09 2012-03-28 IN2012DN02696A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305964A EP2308897A1 (en) 2009-10-09 2009-10-09 Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
US26602009P 2009-12-02 2009-12-02
PCT/EP2010/065085 WO2011042534A1 (en) 2009-10-09 2010-10-08 Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer

Publications (1)

Publication Number Publication Date
IN2012DN02696A true IN2012DN02696A (en) 2015-09-04

Family

ID=41682879

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2696DEN2012 IN2012DN02696A (en) 2009-10-09 2012-03-28

Country Status (19)

Country Link
US (1) US20120275997A1 (en)
EP (2) EP2308897A1 (en)
JP (1) JP2013507114A (en)
KR (1) KR20120094474A (en)
CN (1) CN102597004A (en)
AR (1) AR078572A1 (en)
AU (1) AU2010305360A1 (en)
BR (1) BR112012008266A2 (en)
CA (1) CA2775634A1 (en)
IL (1) IL219034A0 (en)
IN (1) IN2012DN02696A (en)
MA (1) MA33668B1 (en)
MX (1) MX2012004059A (en)
NZ (1) NZ599097A (en)
RU (1) RU2012113418A (en)
TN (1) TN2012000151A1 (en)
TW (1) TW201118168A (en)
WO (1) WO2011042534A1 (en)
ZA (1) ZA201202291B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013125221A1 (en) * 2012-02-21 2013-08-29 静岡県 Affinity ligand for antibody purification
WO2014167969A1 (en) * 2013-04-08 2014-10-16 塩野義製薬株式会社 Method for detecting colon cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (en) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU4441799A (en) * 1998-06-15 2000-01-05 Research Foundation Of The State University Of New York, The Monoclonal antibodies that recognize antigens associated with tumor metastasis
SI2177536T1 (en) * 2006-03-30 2014-09-30 Glaxo Group Limited Antibodies against amyloid-beta peptide
JP5317697B2 (en) * 2006-08-14 2013-10-16 中外製薬株式会社 Diagnosis and treatment of cancer using anti-Desmoglein3 antibody
GB0619291D0 (en) * 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
FR2907341B1 (en) * 2006-10-18 2012-08-17 Pf Medicament USE OF ANTI-CD151 ANTIBODY FOR THE TREATMENT OF CANCER
EP2222709B1 (en) * 2007-11-30 2016-11-23 Glaxo Group Limited Antigen-binding constructs
FR2929946B1 (en) * 2008-04-11 2010-05-28 Pf Medicament NOVEL ANTI-CD151 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
TW201118168A (en) 2011-06-01
KR20120094474A (en) 2012-08-24
JP2013507114A (en) 2013-03-04
WO2011042534A1 (en) 2011-04-14
AR078572A1 (en) 2011-11-16
RU2012113418A (en) 2013-11-20
EP2486057A1 (en) 2012-08-15
CN102597004A (en) 2012-07-18
AU2010305360A1 (en) 2012-04-19
CA2775634A1 (en) 2011-04-14
US20120275997A1 (en) 2012-11-01
TN2012000151A1 (en) 2013-12-12
MA33668B1 (en) 2012-10-01
MX2012004059A (en) 2012-05-22
IL219034A0 (en) 2012-06-28
ZA201202291B (en) 2012-11-28
BR112012008266A2 (en) 2019-09-24
NZ599097A (en) 2014-03-28
EP2308897A1 (en) 2011-04-13

Similar Documents

Publication Publication Date Title
BR112012012396A2 (en)
BR112012008267A2 (en)
BR112012008195A2 (en)
BRPI0925311A2 (en)
BRPI0924307A2 (en)
BR122021004633A2 (en)
BR122017024704A2 (en)
BR112012003853A2 (en)
BR112012012080A2 (en)
BR112012009797A2 (en)
BR112012009446A2 (en)
BR112012009703A2 (en)
BR112012010357A2 (en)
BR122019005883A2 (en)
BR112012000159A2 (en)
BR112012014856A2 (en)
BRPI0924534A2 (en)
BR112012007672A2 (en)
BR112012000255A2 (en)
BR112012000156A2 (en)
BRPI0924617A2 (en)
BR122017013721A2 (en)
BR112012009404A2 (en)
BR112012016234A2 (en)
BRPI0925022A2 (en)